$ONCO Cashflow Statement | Understand Stock

$ONCO

$0.49 +$0.02 (4.07%) Pre-market

$ONCO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on impairment of goodwill
Loss on impairment of ENTADFI
Loss on impairment of intangibles
Amortization of debt discount
Amortization of debt discount - related party
Loss on related party receivable
Loss on extinguishment of note payable
Loss on extinguishment of Series C preferred stock
Loss on issuance of preferred stock and warrants
Depreciation and amortization
Fair value of subscription agreement liability
Issuance of restricted common stock
Change in fair value of contingent warrant liability
Depreciation expense
Net periodic pension benefit cost
Stock-based compensation
Loss on impairment of other long-lived assets
Loss on impairment of inventory of ENTADFI
Change in fair value of contingent warrant liabilities
Change in fair value of Series D warrant liability
Change in fair value of Series D derivative liability
Change in fair value of Series E warrant liability
Change in fair value of Series E derivative liability
Change in fair value of subscription agreement liability
Recovery of related party receivable
Provision for excess inventory
Loss on disposal of property and equipment
Gain on forgiveness of accounts payable
Deferred tax benefit
Amortization of deferred offering costs
Gain on settlement of contingent warrant liabilities

Changes in assets and liabilities:
Accounts receivable
Inventory
Investor receivable
Prepaid expenses and other assets
Receivable from related parties
Prepaid expenses, long-term
Deferred offering costs
Accounts payable
Accrued expenses
Net cash used in operating activities

Cash flows from investing activities
Acquisition of assets, including transaction costs of $79,771
Acquisition of assets
Cash acquired through business combination
Deposit made in connection with asset purchase agreement
Purchase of other long-lived assets
Net advances to related parties
Receivable from related party
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discount
Proceeds from issuance of notes payable - related party
Proceeds from issuance of notes payable
Payment of financing costs
Payment on note payables
Payment of redemption of Series C Preferred Stock
Proceeds from exercise of preferred investment options, net
Proceeds from exercise of stock options
Proceeds from issuance of common stock and warrants in private placements, net of placement agent discount
Payments of initial public offering costs
Payment of private placement issuance costs
Proceeds from exercise of warrants
Proceeds from issuance of Series D Preferred Stock and warrants
Proceeds from issuance of Series E Preferred Stock and warrants
Proceeds from issuance of Series C Preferred Stock and warrants
Proceeds from issuance or sale of common stock
Cash in lieu of shares
Deferred financing costs
Purchase of treasury shares

Net cash provided by financing activities
Effect of exchange rate changes on cash
Net increase (decrease) in cash
Cash, beginning of period
Cash, end of period
Cash paid for interest
Noncash investing and financing activities:
Inventory and intangible assets acquired through issuance of notes payable
Incremental fair value of exchanged preferred investment options
Deferred offering costs included in accounts payable and accrued expenses
Incremental fair value of preferred investment options exchanged in connection with August private placement
Issuance of restricted stock
Payment of accrued bonus through related party receivable
Conversion of Series Seed Preferred Stock to common stock upon initial public offering
Recognition of contingent warrant liability
Warrants issued for settlement of contingent warrants
Deferred offering costs previously included in prepaid expenses
Effect of business combination (Note 5)
Conversion of Series B Preferred Stock to common stock
Settlement of note payable through issuance of Series A convertible preferred stock
Exercise of pre-funded warrants
Restricted stock forfeitures
Conversion of Series C preferred stock to common stock
Recognition of Series D derivative liabilities
Recognition of Series D preferred stock
Recognition of Series E warrant liabilities
Recognition of Series E derivative liabilities
Reclassification of Series D warrant liabilities to equity
Reclassification of Series E warrant liabilities to equity
Series C preferred stock exchanged for Series D preferred stock
Settlement of note payable through issuance of Series D preferred stock
Settlement of related party note payable and accrued interest through issuance of common stock
Settlement of subscription agreement liability
Establishment of operating right-of-use asset
Conversion to equity of non-controlling interest
D&O insurance premium financed
Receivable from shareholders for shares issued
Measurement Period Adjustments from Proteomedix acquisition
Adjustment to redeemable Series C preferred stock
Deemed dividend Series C preferred stock

Comments